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Abstract The objectives of this study were to determine whether the main opioid receptor (OPRM1) is present on human granulosa
cells and if exogenous opiates and their antagonists can inﬂuence granulosa cell vascular endothelial growth factor (VEGF) produc-
tion via OPRM1. Granulosa cells were isolated from women undergoing oocyte retrieval for IVF. Complementary to the primary cells,
experiments were conducted using COV434, a well-characterized human granulosa cell line. Identiﬁcation and localization of opiate
receptor subtypes was carried out using Western blot and ﬂow cytometry. The effect of opiate antagonist on granulosa cell VEGF
secretion was assessed by enzyme-linked immunosorbent assay. For the ﬁrst time, the presence of OPRM1 on human granulosa cells
is reported. Blocking of opiate signalling using naloxone, a speciﬁc OPRM1 antagonist, signiﬁcantly reduced granulosa cell-derived
VEGF levels in both COV434 and granulosa-luteal cells (P < 0.01). The presence of opiate receptors and opiate signalling in granu-
losa cells suggest a possible role in VEGF production. Targeting this signalling pathway could prove promising as a new clinical option
in the prevention and treatment of ovarian hyperstimulation syndrome.
© 2015 The Authors. Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
KEYWORDS: granulosa cells, naloxone, OHSS, opioid receptor, OPRM1, VEGF
http://dx.doi.org/10.1016/j.rbmo.2015.12.006
1472-6483/© 2015 The Authors. Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Reproductive BioMedicine Online (2016) 32, 316–322
www.sciencedirect .com
www.rbmonl ine.com
Introduction
Ovarian hyperstimulation syndrome (OHSS) is a potentially
serious complication of iatrogenic ovarian stimulation carried
out for assisted reproduction techniques (Gomez et al., 2010).
It is characterized by ovarian enlargement caused by mul-
tiple ovarian cysts and the shift of intravascular ﬂuid to the
extracellular compartments, mostly into the abdominal cavity,
resulting in haemoconcentration and hypercoagulability
(Elchalal and Schenker, 1997; Kaiser, 2003). After ovarian
stimulation for IVF, the reported incidence of OHSS ranges
from 20–33% for the mild form, 3–6% for the moderate form
and about 1–2% for the severe form (Al-Inany and Aboulghar,
2001; Delvigne and Rozenberg, 2002).
Granulosa cell-derived vascular endothelial growth factor
(VEGF) has been implicated as the main culprit in the patho-
genesis of iatrogenic OHSS (Lee et al., 1997; Neulen et al.,
1995). By binding to the VEGF2 receptor on endothelial cells,
VEGF increases vascular permeability, loosens intercellular
junctions, leading to ﬂuid extravasation (Soares et al., 2008).
In granulosa cells, human chorionic gonadotropin (hCG) binding
upregulates the hypoxia inducible factor 1α (HIF-1α) and its
target gene VEGF via cyclic adenosine monophosphate/
Protein kinase A (cAMP/PKA), further aggravating OHSS (van
den Driesche et al., 2008).
In addition to the inﬂuence of hCG on VEGF hypersecre-
tion, hyperinsulinaemia secondary to insulin resistance has
also been shown to increase granulosa-cell VEGF secretion.
Stanek et al. (2007) reported that co-incubation of granu-
losa cells with LH and insulin led to a dose-dependent in-
crease in VEGF, implying that hyperinsulinaemia potentiates
gonadotrophin-induced VEGF hypersecretion in vitro (Stanek
et al., 2007). This concept was corroborated clinically by a
signiﬁcant reduction in OHSS after pretreating IVF patients
with the insulin sensitizer metformin (Palomba et al., 2011).
The complex regulation of HIF-1α activity in granulosa cells
under normoxic conditions requires input from multiple sig-
nalling pathways (Alam et al., 2009). Evidence from other cell
models suggests that ERK1/2 signalling is involved in HIF-1α
regulation and induction by directly phosphorylating HIF-1α
and by enhancing HIF-1 binding activity (Bardos and Ashcroft,
2005; Doronzo et al., 2006; Sutton et al., 2007). ERK1 and ERK2
belong to the mitogen-activated protein kinase family and ac-
tivate various transcription factors, including JUN that induce
the transcription of fos and jun genes. It has been shown that
the opioid receptors are functionally coupled to the mitogen-
activated protein kinase signalling pathway (Fukuda et al.,
1996). Four major receptor classes for endogenous opioids
have been described: μ (OPRM1), δ (OPRD1), κ (OPRK1) and
nociceptin receptors (OPRL1) (Corbett et al., 2006). Stimu-
lation of the OPRM1 receptor induces the expression of c-fos
and junB genes, thereby increasing the number of activator
protein 1 complexes. The activator protein 1 binding site was
found in the VEGF gene promotor region (Shoda et al., 2001;
Tischer et al., 1991). It follows that opiate binding to OPRM1
could increase production of VEGF via this pathway.
Prompted by the evidence for an intrafollicular opioid
system in mammals (Dell’Aquila et al., 2002; Hamada et al.,
1995; Kaminski et al., 2000, 2004; Slomczynska et al., 1997),
and supported by data from previous clinical trials on the ad-
ministration of opioid antagonists in the context of
gynaecological endocrinology (Hadžiomerovic´-Pekic´ et al.,
2010; Leyendecker et al., 1993; Sir-Petermann et al., 1998),
we set out to elucidate the presence of opioid receptors in
human granulosa cells and to test the effects of exogenous
opiates on granulosa cell VEGF production. This study is the
necessary ﬁrst step to elucidate the role of endogenous opioids
in human granulosa cells as a component of the follicular
microenvironment.
Materials and methods
Granulosa cell isolation and culture
In 12 women aged 35.4 ± 5.4 years with tubal factor infer-
tility or male factor infertility undergoing IVF, transvaginal
follicle aspiration was carried out 36 h after triggering ﬁnal
oocyte maturation with subcutaneous administration of
10,000 IU hCG (Pregnyl®). Oocytes were recovered and used
for planned infertility treatment. The remaining follicular ﬂuid
was then pooled for each patient. Primary granulosa cells were
separated in 40% Percoll solution in Dulbecco’s phosphate buff-
ered saline (DPBS; Sigma-Aldrich, St Louis, MO, USA) by cen-
trifugation at 500 g in a swing bucket centrifuge for 35 min
at 10°C. The granulosa cells accumulated in the interphase
were then collected in phosphate buffered saline and cen-
trifuged again at 200 g for 15 min. The cell pellet was resus-
pended with Dulbecco’s modiﬁed Eagle Medium: Nutrient
Mixture F-12 (DMEM/F12; Sigma-Aldrich, St Louis, MO, USA)
supplemented with 10% fetal bovine serum and 1% Penicillin–
Streptomycin (Biochrom, Berlin, Germany; Thermo Fisher Sci-
entiﬁc, Waltham, MA, USA). For all subsequent experiments
with primary granulosa cells, culturing medium was re-
placed at least twice before proceeding in order to remove
potential non-adhering cell contaminants such as erythro-
cytes and leukocytes.
In parallel, COV434, a well-characterized, stable, com-
mercially available human granulosa cell line (ECACC®-
Sigma) was used, which was ﬁrst described by Zhang et al.
(2000). COV434 and human primary granulosa cells were
separately cultured in Dulbecco’s Modiﬁed Eagle Medium/
Nutrient Mixture F-12 containing 10% FBS and 1% Penicillin–
Streptomycin. Before the experiment, representative COV434
cell line samples and primary granulosa cell samples were
phenotypically validated by western blotting for aromatase
and FSH receptor (FSHR; data not shown). The expression of
FSH receptor in the human female is highly speciﬁc for granu-
losa cells (Simoni et al., 1997).
Gel electrophoresis and Western blot analysis
Primary granulosa cells and COV434 cells were separately
pooled and lysed in radioimmunoprecipitation assay buffer con-
taining 50 mM Tris, 1% IGEPAL CA-630, and 0.5% sodium de-
oxycholate, 1% sodium dodecyl sulfate and 150 mM sodium
chloride (Sigma-Aldrich, St Louis, MO, USA) supplemented with
Complete Mini EDTA-free Protease Inhibitor (Roche, Basel, CH).
The protein lysates were then snap-frozen in liquid nitrogen
and stored at −80°C until analysis. HepG2 cell line (ATCC®
HB-8065™) extracts served as positive controls. Samples
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wereheated at 70°C for 10 min and then separated on sodium
dodecyl sulfate polyacrylamide gel electrophoresis in a XCell
mini cell system using 10% Bis-Tris protein gel (Thermo Fisher
Scientiﬁc, Waltham, MA, USA). Proteins were subsequently
blotted onto low ﬂuorescent polyvinyldiﬂuorene mem-
branes (Immobilon FL, Merck Millipore, Billerica, MA, USA).
A polyclonal antibody directed against the N-terminal part of
the receptors (sc-7489) was used to detect OPRM1. The signal
was detected using a secondary anti-goat IRDye680 LT (LI-
COR Biosciences, Lincoln, NE, USA, dilution 1:25,000 in a com-
mercial ﬂuorescent Western blot blocking buffer (Rockland
Inc, Limerick, PA, USA) supplemented with 0.1% Tween and
0.02% sodium dodecyl sulfate as recommended by the anti-
body supplier. Blots were read-out on an Odyssey scanner (LI-
COR Biosciences, Lincoln, NE, USA) using Odyssey software.
For all blots, manual linear sensitivity adjustment was used
on the whole image. To conﬁrm labelling speciﬁcity, one
control consisted of a separate blot of a HepG2 lysate in which
the primary antibody was omitted (secondary antibody only).
Additionally, a blocking experiment was carried out with the
immunizing peptide (ﬁve-fold excess, sc-7489 P, Santa Cruz
Biotechnology, Dallas, TX, USA) and titration experiments.
After the read-out, all blots were subjected to a protein stain-
ing using Ponceau S solution (Sigma-Aldrich, St Louis, MO, USA)
to test for transfer efﬁcacy, to control for loading and to dis-
criminate the molecular weight markers.
Flow cytometric analysis
COV434 cells, primary granulosa cells and HepG2 cells (posi-
tive control) were detached using Accutase® (Sigma-Aldrich,
St Louis, MO, USA) to preserve membrane epitopes. In brief,
cells were then washed once in Dulbecco’s phosphate-
buffered saline (DPBS) (Sigma-Aldrich, St Louis, MO, USA) and
resuspended in staining buffer (DPBS with 1% bovine serum
albumin) and blocked for 30 min at room temperature. After
two washing steps, the cell suspensions were incubated with
OPRM1 goat polyclonal antibody in staining buffer (sc-7489,
Santa Cruz Biotechnology, Dallas, TX, USA; dilution 1:50, 1 h
at 4°C). For ﬂuorescent detection, a Phycoerythrin (PE)-
coupled donkey anti-goat secondary antibody was used
(Jackson Immunoresearch, dilution 1:100, 30 min at room tem-
perature). Samples were then measured on a FACS Calibur
cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Non-
speciﬁc staining and autoﬂuoresence was tested using primary-
antibody free or unstained samples. To discriminate between
live and dead cells, 7-AAD was used. For analysis and visual-
ization, FlowJo software v8.8.7 (FlowJo, Ashland, OR, USA)
was used. Cells were differentiated from debris using forward
and side scatter light characteristics and only 7-AAD nega-
tive cells were analysed for OPMR1 expression.
Granulosa cell stimulation experiments
COV434 cells were propagated in T75 ﬂasks until 70–80%
conﬂuency. After enzymatic detachment with Trypsin-EDTA
(Sigma-Aldrich, St Louis, MO, USA), cells were seeded in 96
well plates at a density of 20,000 cells/well/300 μl. Cell count-
ing was carried out in duplicate with the trypan blue exclusion
test and a hemocytometer. Primary granulosa cell aliquots
after density gradient separation from each primary granu-
losa cell sample were taken and viability and total viable cell
count was assessed as described above. Primary cells were
seeded at a concentration of 17,500 cells per well in dupli-
cate for each stimulation agent or control. Culturing medium
consisted of a well-established serum free granulosa cell ex-
pansion medium containing phenol red free DMEM/F12 with
5 μg/ml transferrin, 5 ng/ml selenium (both Sigma-Aldrich,
St Louis, MO, USA), 10 μg/ml aprotinin (Carl Roth, Karlsruhe,
Germany), and 25 μg/ml human low-density lipoprotein
(Sigma-Aldrich, St Louis, MO, USA) (Stanek et al., 2007). The
serum free medium contained neither antibiotics nor
antimycotics. The challenging agents were added in eight rep-
licates per group as follows: serum free medium (control),
human recombinant insulin (positive control; Sigma-Aldrich,
St Louis, MO, USA; 10 ng/ml) and naloxone hydrochloride (an-
tagonist; Amo Med, Wien, Austria; 2 ng/ml, 10 ng/ml).
COV434 cells and primary cells were incubated for 72 h at
37°C with 5% CO2 in a humidiﬁed chamber. Culture superna-
tants were sampled after 72 h and stored at −20°C until
analysis.
Immunoassay for VEGF
A human enzyme linked immunosorbent assay (ELISA) kit suited
for cell culture samples was used to determine VEGF con-
centrations in COV434 granulosa cell and primary granulosa
cell culture supernatant (Quantikine VEGF ELISA; R&D Systems,
Minneapolis, MN, USA). All measurements were made in du-
plicates. The lower detection limit was 5 pg/ml, intra-and
inter-assay precision (coefﬁcient of variation) were 2.9% and
6.2%, respectively.
Viable cell counting assay
After sampling, themicrotiter plates were inverted and blotted
against absorbent paper towels. Subsequently, cells were cul-
tured in 100 μl phosphate buffered saline with Ca2+/Mg2+
supplemented with 10% cell counting kit-8 solution (CCK-8
assay, Sigma). The cells were then incubated for 4 h at 37°C,
5% CO2. The absorbance at 450 nm corrected at 600 nm (ref-
erence wavelength) was then measured with a microplate
reader (Tecan Genios Pro). Raw measurements were blanked
for culturing medium. The microtiter plates were tested for
consistency in cell viability to ensure that the number of viable
granulosa cells per well did not affect our VEGF results.
Statistical analysis
For semiquantitative Western blot analyses, uncompressed
16 bit tagged image ﬁle format (tif) images acquired from the
Odyssey scanner were analysed with ImageStudioLite, version
4.0.21 for Mac OS X (LI-COR Biosciences, Lincoln, NE, USA).
Median background correction was applied for all segments.
COV434 ELISA data represent the viable cell adjusted mean
± conﬁdence interval of eight observations from three inde-
pendent experiments using a general linear model with the
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Holm–Sidak method for post-hoc multiple comparisons. For
primary granulosa cell experiments, duplicate VEGF mea-
surements were averaged per challenging agent for each
subject. All VEGFmeasurements were normalized to the CCK-8
value of the respective control on a per-patient level. Nor-
malized data were then log transformed and a repeated mea-
sures analysis of variance was conducted. Post-hoc comparisons
were conducted applying the Holm–Sidak post hoc correc-
tion for multiple testing.
Statistical analyses were carried out using GraphPad Prism,
Version 6.01 (GraphPad Software, San Diego, CA, USA), and
SPSS 22.0 (IBM Corp., Armonk, NY, USA). P < 0.05 was con-
sidered signiﬁcant.
Ethical approval
The study was approved by the Ethics Commission of the
Medical University of Innsbruck (UN4844, 29.10.2012). All par-
ticipants signed an informed consent form.
Results
Opiate receptor proﬁling
In both COV434 and pooled primary granulosa cells isolated
from follicular ﬂuid from women during IVF, a clear band at
about 44 kDa corresponding to the OPRM1 protein was ob-
served in whole cell lysates (Figure 1). In crude HepG2 lysates,
a band with the same molecular weight was detected (posi-
tive control) (Figure 1). No immunoreactivity was detected
when either the primary antibody was depleted using a ﬁve-
fold excess of a speciﬁc blocking peptide or when the primary
antibody was omitted (negative controls) (Figure 1). In the
antibody titration experiments, an additional band at about
36 kDa was observed (data not shown). In ﬂow cytometry, the
antibody directed against the N-terminus of OPRM1 recep-
tor revealed a positive signal at the cell surface conﬁrming
the Western blot result (Figure 2).
Granulosa cell incubation experiments
After 72 h of culture, the number of cells was not different
in the experimental and control wells, as veriﬁed by no dif-
ferences in absorbance between these wells as determined
by the cell counting assay (data not shown).
When COV434 granulosa cells were exposed to the opiate
antagonist naloxone (2 ng/ml) a signiﬁcant decrease in VEGF
levels compared with controls was observed (P = 0.0032)
(Figure 3A). On average, naloxone reduced VEGF concen-
trations by 15%. Increasing the concentration of the opiate
antagonist to 10 ng/ml further increased this effect (17%
reduction, P = 0.008). In contrast, after stimulation with re-
combinant insulin, a signiﬁcant increase in VEGF could be de-
tected after 3 days of culture compared with exposure to
insulin-free mock medium (P < 0.0001). When COV434 cells
were incubated with insulin, an average increase in VEGF levels
of 21.3% could be observed.
In primary granulosa cells, the addition of opiate antago-
nists led to a decrease of VEGF for both naloxone 2 ng/ml and
10 ng/ml (P = 0.0010 and P = 0.0098, respectively) (Figure 3B).
When the cells were challenged with insulin, no effect on VEGF
levels could be observed. As shown in Figure 3B, maximum
relative reduction of VEGF secretion after naloxone expo-
sure was 23.6%.
Discussion
In this study, we report for the ﬁrst time the presence of opioid
receptors on the cell surface of human granulosa cells. Fo-
cusing on OPRM1, we conﬁrmed the speciﬁcity of our ﬁnd-
ings by conducting blocking experiments, and veriﬁed the
result with a second, independent method of ﬂow cytometry.
By modulating key hormones such as LH, FSH, prolactin and
thyroid stimulating hormone, the opioid system consider-
ably inﬂuences the central control of female reproductive
function. Similarly, there is evidence for peripheral effects
of opioids on endocrine responsive tissues (Vuong et al., 2010).
Recently, opioid receptors have been shown to be present in
the male germ cells (Agirregoitia et al., 2006, 2012). More-
over, beta-endorphin as a possible follicular paracrine signal
has been studied in the bovine ovary. The addition of beta-
endorphin to bovine oocytes cultured in standard expansion
medium signiﬁcantly inhibited oocyte maturation to meta-
phase II stage and increased the rate of oocytes arrested in
metaphase I, an effect that was absent upon the addition of
LH, FSH and 17ß-estradiol to the culture medium (Dell’Aquila
et al., 2002).
Our in-vitro results complement previous clinical ﬁnd-
ings, which showed that, in fertile women, follicular ﬂuid con-
centrations of beta-endorphin and met-enkephalin, the
primary ligands for OPRM1 and OPRD1, respectively, have been
found to be 10–40 times higher than the corresponding serum
values (Petraglia et al., 1985). Whether this phenomenon is
caused by local production of opiates or secondary to accu-
mulation from serum is unknown. In addition, beta-endorphin,
but not met-enkephalin levels, were found to be menstrual
cycle phase-dependent, peaking at the occurrence of ovula-
tion (Petraglia et al., 1985). As shown by our previous work,
administration of the opiate antagonist naltrexone to
+ Blocking peptide
45
kDa
Figure 1 Detection of OPRM1 by Western Blot analysis of HepG2
(positive control), human granulosa cell line (COV434) and primary
granulosa cell (PGC) whole cell lysates. In the presence of the
immunizing peptide, the detected signal is absent. Dotted lines
indicate membrane cutting lines. The ﬁgure is representative of
at least three independent experiments.
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hyperinsulinaemic women with polycystic ovary syndrome sig-
niﬁcantly decreased insulin levels (Hadžiomerovic´-Pekic´ et al.,
2010).
Experimental evidence shows that endogenous opioids
stimulate angiogenesis in other cells, such as retinal epithe-
lial cells and dermal microvascular endothelial cells, through
a stimulatory effect on VEGF production and that this effect
can be attenuated by inhibiting the ERK1/2 signalling pathway
or by administering methyl-naltrexone (Dai et al., 2010;
Singleton et al., 2006; Ye et al., 2012).
To date, 18 isoforms of the human μ opioid receptor are
known. The detected band in the Western blot for OPRM1 of
44 kDa corresponds to the canonical sequence of isoform 1
(UniProtConsortium, 2014). The additional signal at approxi-
mately 36 kDa may correspond to isoform 14 (μ3), but further
conﬁrmatory experiments are necessary to conﬁrm this ﬁnding
(UniProtConsortium, 2014). In our stimulation experiments,
we administered insulin as well as a speciﬁc OPRM1 antago-
nist and measured changes in VEGF production in cell culture.
As a result, we found an increase in VEGF release in COV434
after exposure to insulin and a decrease in production fol-
lowing antagonist administration. In contrast, primary granu-
losa cells from healthy women did not respond with an increase
in VEGF release after insulin challenge. This ﬁnding is in line
with previous work showing that insulin only affects granu-
losa cell VEGF release in the presence of hCG (Agrawal et al.,
2002), although conﬂicting results have been reported (Stanek
et al., 2007).
We conducted a cell counting assay to exclude a possible
cytotoxic or proliferative effect of the challenging agents on
the number of viable granulosa cells per well. Results con-
ﬁrmed that the observed differences in VEGF levels are not
due to differences in cell density per well. Our ﬁndings are
consistent with previous trials assessing the DNA content of
macaque granulosa cells and human granulosa cells from
healthy women after stimulation with insulin, which like-
wise found no cytotrophic effect (Martinez-Chequer et al.,
2003; Stanek et al., 2007).
HepG2
FL2-H: OPRM1 + DaG-PE
COV434
FL2-H: OPRM1 + DaG-PE
PGC
FL2-H: OPRM1 + DaG-PE
Figure 2 Detection of OPRM1 by ﬂow cytometry. Flow cytometry with live-cell gating applying 7-AAD on HepG2, COV434 and primary
granulosa cells (PGC) using an N-terminal OPRM1 antibody (bold line). Unstained controls or cells stained only with the secondary
antibody are represented by dotted lines or thin lines, respectively. The ﬁgure is representative of at least three independent experiments.
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Figure 3 Effect of insulin and naloxone on granulosa cell VEGF secretion. VEGF concentrations of culture supernatant after 3 days
of culture in the presence of recombinant human insulin (10 ng/ml) or naloxone (2 ng/ml [NX2], 10 ng/ml [NX10]), compared with
control. Values represent relative change of viable cell-corrected means of three independent experiments with eight replicates per
experimental setup (COV434; 3A) or relative change of viable cell-corrected means of 12 participants (primary granulosa cells; 3B).
Error bars indicate mean with 95% CI. NS, not signiﬁcant; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.
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As identiﬁed by Western Blotting and ﬂow cytometry, the
main opiate receptor subtype (OPRM1) is present on the cel-
lular surface of granulosa cells. Moreover, the administra-
tion of a highly speciﬁc OPRM1 antagonist (naloxone) results
in a signiﬁcant reduction in VEGF secretion in both non-
luteinized (COV434 cells) and luteinized human granulosa cells.
Future studies elucidating the opiate signalling pathways and
other possible mechanisms of action of opiates within the fol-
licular microenvironment are warranted.
In conclusion, our study provides new insight into the physi-
ology of the follicular microenvironment, and strongly sug-
gests that opioids may play a role in regulating the function
of granulosa cells, in the development of ovarian follicles, or
both. Our results hold promise for possible new therapeutic
options in the prevention and treatment of OHSS, and should
serve as the basis for future studies further evaluating the clini-
cal implications of these ﬁndings.
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